Peptide Synthesis Market By Product (Reagents & Consumables, Equipment and Others), By Technology (Hybrid Technology, Solid Phase Peptide Synthesis (SPPS), and Liquid Phase Peptide Synthesis (LPPS)), By Application (Infectious Diseases, Cardiovascular Disease, Respiratory Disease, and Others) and By End-Users (Pharmaceutical & Biotechnology Companies, Research Institutes, Contract Research Organization (CRO), and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

• Thermo Fisher Scientific
• Kaneka Corporation
• Merck KGaA
• GenScript Biotech Corporation
• Syngene
• CEM Corporation*
• Lonza
• Biotage AB
• Novo Nordisk A/S

Recent News:

• Bachem Group inked a long-term follow-on contract for peptides in December 2022. A five-year contract, spanning from 2025 to 2029, has been signed, with a minimum order volume of CHF 1 billion overall. The Bachem Group is working on a capacity expansion investment program at all of its locations. The capacity of the state-of-the-art, large-scale peptide and oligonucleotide synthesis plant at the Bubendorf location has doubled.
• CEM Corporation introduced their next generation automated microwave peptide synthesizers, called "Liberty 2.0," in April 2022. The recently released Liberty 2.0 series, which has increased reagent locations and automation possibilities, has improved peptide purity, extraordinary automation dependability, and remarkable synthesis efficiency, all contributing to the advancement of SPSS technology. The novel headspace flushing procedure of the Liberty 2.0 family of instruments promotes a cleaner reaction vessel environment and aids in delivering previously unheard-of levels of peptide purity for sequences longer than 100 amino acids.